15-mg Dose with Corticosteroid Taper Shows Higher Remission Rate Than Placebo From Weeks 12-52 in Study

A recent study indicated that a 15-mg dose combined with a corticosteroid taper regimen achieved a higher rate of sustained remission compared to a placebo. Researchers observed this outcome from week 12 to week 52 of the study. The study specifically tracked whether participants maintained remission over a period of 40 weeks, beginning at week 12 and ending at week 52. The data revealed that the 15-mg dose, administered in conjunction with a corticosteroid taper regimen, demonstrated a statistically significant improvement in maintaining remission when contrasted with the placebo group.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Related posts:

Global Obesity Crisis: 1 in 6 Young People Predicted to Face Obesity by 2050, Study Warns IRA Drug Pricing Reforms: Experts Discuss Reimbursement Complexities and Potential Impact on Medication Access Biotech Sector Update: Recent Findings and Developments Reported Asembia Summit: IRA Drug Negotiation to Reshape Medicare Part B and Commercial Healthcare Delivery

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後